<DOC>
	<DOCNO>NCT00644124</DOCNO>
	<brief_summary>The purpose study determine select dose aflibercept combine R-CHOP treatment ( Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal Methotrexate ) administer every 2 week every 3 week , non Hodgkin B-cell lymphoma , determine body handle aflibercept administer R-CHOP .</brief_summary>
	<brief_title>Aflibercept Standard Chemotherapy ( R-CHOP ) First Line Non Hodgkin B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Patients nonHodgkin Bcell lymphoma , good condition , previously treat Contraindication drug contain RCHOP ( Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/ intrathecal Methotrexate ) Less 42 day elapse prior major surgery ( 28 day prior surgery ) time inclusion Cerebral leptomeningeal involvement . History another neoplasm ( Adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , cancer patient disease free &gt; 5 year allow ) Participation another clinical trial concurrent treatment investigational drug within 30 day prior first drug intake Any acute chronic medical condition , could impair ability patient participate study could interfere interpretation study result Uncontrolled diabetes mellitus Uncontrolled hypertension Abnormal kidney function Evidence clinically significant bleed diathesis , nonhealing wound underlie coagulopathy Pregnant breastfeeding woman , patient reproductive potential ( male , female ) without effective method contraception History hypersensitivity Trap agent recombinant protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>angiogenesis inhibitor</keyword>
	<keyword>CHOP protocol</keyword>
</DOC>